There is no clinically validated human dose you can look up here, because for this compound one does not exist in the way regulated drugs have. We report what research and regulators actually say, and nothing more.
What it is
Retatrutide is a triple hormone-receptor agonist: it hits GLP-1 and GIP like tirzepatide, plus a third target, the glucagon receptor, which appears to raise energy expenditure. It is the most-watched next-generation metabolic drug candidate.
The evidence, stated plainly
Phase 3 trials (the TRIUMPH program) have reported striking weight loss, with company figures around an average of 24 to 29% of body weight over roughly 15 months, alongside more gastrointestinal side effects than milder agents. Promising, but the pivotal program is still reporting and it is not approved.
In human clinical trials, not yet approved. We label evidence by its strongest honest tier, never by a vendor’s enthusiasm.
Half-life & timing
Trial pharmacokinetics support roughly weekly dosing; precise figures come from Lilly trial data rather than a finalized label.
Regulatory status
Not FDA-approved as of 2026. It is legally available only through Eli Lilly clinical trials; any "retatrutide" sold to consumers outside those trials is unregulated, unverified for purity, and not an approved product. Because it shares the GLP-1 mechanism, it should never be stacked on top of semaglutide or tirzepatide.
Storage & handling
No consumer product exists, so there is no approved storage guidance. Gray-market material has no verified handling standard.
Whatever dose a protocol or provider gave you, converting it to syringe units is where errors turn into 10× mistakes. Our calculator does only that conversion — it never invents the dose.
Open the reconstitution calculatorThe honest bottom line
Retatrutide may become a landmark obesity drug, but "in advanced trials" is not "approved." The honest position today: wait for approval and a prescriber, or enroll in a legitimate trial. Consumer vials are a gamble on identity, purity, and dose.
Sources
- Eli Lilly TRIUMPH Phase 3 announcements, 2025-2026.
- GoodRx and clinical summaries of retatrutide trial weight-loss figures.
- FDA approval-status trackers, 2026 (not approved).
Sourcing reflects literature available at publication and may change. See How We Rate Evidence.